Engel Jessica M, Stankowski-Drengler Trista J, Stankowski Rachel V, Liang Hong, Doi Suhail A, Onitilo Adedayo A
1 Stevens Point Cancer Center, Marshfield Clinic and Saint Michael's Hospital, Stevens Point, WI.
AJR Am J Roentgenol. 2015 Apr;204(4):898-902. doi: 10.2214/AJR.14.12666.
The value of annual mammography remains an area of debate because of concerns regarding risk versus benefit. The potential for harm due to overdiagnosis and treatment of clinically insignificant cancers may not be captured by breast cancer-specific mortality. Instead, we examined all-cause mortality as a function of missed annual mammography examinations before breast cancer diagnosis.
Primary breast cancer cases diagnosed in the Marsh-field Clinic Health System from 2002 through 2008 were identified for retrospective review, and whether annual mammography examinations had been performed in the 5 years before diagnosis was assessed.
Analyses were performed on 1421 women with breast cancer. After adjustment of data for age, comorbidity status, a family history of breast cancer, insurance status, medical encounter frequency, and the calendar year, women who had missed any of the previous five annual mammography examinations had a 2.3-fold increased risk of all-cause mortality compared with subjects with no missed mammography examinations (hazard ratio=2.28; 95% CI, 1.58-3.30; p<0.0001). Additionally, an analysis by the number of missed annual mammography examinations showed a progressive increase in hazard as the number of missed mammography studies increased.
These results suggest that annual mammography before breast cancer diagnosis is predictive of increased overall survival. A stepwise decline in overall survival was noted for each additional missed mammography examination. These results are similar to findings in the literature for breast cancer-specific mortality and illustrate the importance of recommending annual mammography to all eligible women.
由于对风险与获益的担忧,年度乳腺钼靶检查的价值仍是一个存在争议的领域。临床意义不显著的癌症过度诊断和治疗所导致的潜在危害可能无法通过乳腺癌特异性死亡率体现出来。相反,我们将全因死亡率作为乳腺癌诊断前年度乳腺钼靶检查漏检情况的函数进行了研究。
确定2002年至2008年在马什菲尔德诊所医疗系统诊断的原发性乳腺癌病例进行回顾性研究,并评估诊断前5年是否进行了年度乳腺钼靶检查。
对1421例乳腺癌女性进行了分析。在对年龄、合并症状态、乳腺癌家族史、保险状况、医疗就诊频率和日历年数据进行调整后,与未漏检乳腺钼靶检查的受试者相比,之前五年中漏检任何一次年度乳腺钼靶检查的女性全因死亡风险增加了2.3倍(风险比=2.28;95%可信区间,1.58 - 3.30;p<0.0001)。此外,根据年度乳腺钼靶检查漏检次数进行的分析显示,随着漏检乳腺钼靶检查次数的增加,风险呈逐步上升趋势。
这些结果表明,乳腺癌诊断前的年度乳腺钼靶检查可预测总体生存率的提高。每多漏检一次乳腺钼靶检查,总体生存率就会出现逐步下降。这些结果与文献中关于乳腺癌特异性死亡率的研究结果相似,说明了向所有符合条件的女性推荐年度乳腺钼靶检查的重要性。